LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Verrica Pharmaceuticals Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERVRCA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / VRCA COVERAGE

What’s moving Verrica Pharmaceuticals Inc. now

Current reporting with the operating signal separated from the noise.

01
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2025 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2025 Earnings Call Transcript

Investors are testing whether Verrica Pharmaceuticals Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript

Investors are testing whether Verrica Pharmaceuticals Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

Investors are testing whether Verrica Pharmaceuticals Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders seem bullish, own 40% and have been buying more recently

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders seem bullish, own 40% and have been buying more recently

The story matters when it changes Verrica Pharmaceuticals Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Verrica Pharmaceuticals Inc. Investor News: Robbins LLP is Investigating Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders

Verrica Pharmaceuticals Inc. Investor News: Robbins LLP is Investigating Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders

Investors are testing whether Verrica Pharmaceuticals Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders

VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders

Investors are testing whether Verrica Pharmaceuticals Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest VRCA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-12 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-14 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-11 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-09 · Period 2026-06-05SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗8-KMaterial company eventFiled 2026-03-11 · Period 2026-03-11SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-20 · Period 2026-06-05SEC ↗4Official SEC filingFiled 2026-06-09 · Period 2026-06-05SEC ↗
EARNINGS / QUARTERLY TRACKER

Verrica Pharmaceuticals Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.